Related Experiment Video
Updated: Mar 19, 2026
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice
Ayşegül Doğan1, Selami Demirci2, Neşe Başak Türkmen3
1Faculty of Engineering and Architecture, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey. aguldgn@gmail.com.
Background:
Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest.
Method:
In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp-C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity.
Results:
Results demonstrated that Heterodinuclear copper(II)Mn(II) complex-P85 combination decreased tumor formation and tumor volume steadily over the course of experiments.
Conclusions:
Overall, Heterodinuclear copper(II)Mn(II) complex-P85 exerted remarkable anti-cancer activity in vivo in C57/B16 mice. Prostate 76:1454-1463, 2016. © 2016 Wiley Periodicals, Inc.
Insights
A new Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 shows significant promise for treating prostate cancer. This combination effectively reduced tumor growth and volume in vivo, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Materials Science
- Pharmacology
Background:
- Prostate cancer is a leading cause of male mortality with increasing incidence.
- Existing therapies face challenges with drug resistance, especially in metastatic stages.
- Novel drug molecules with enhanced membrane permeability and rapid tumor cell killing are needed.
Purpose of the Study:
- To evaluate the efficacy of a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 for prostate cancer treatment in vivo.
- To assess the safety and therapeutic potential of this combination in a preclinical model.
Main Methods:
- A Heterodinuclear copper(II)Mn(II) Schiff base complex was formulated with P85.
- Tramp-C1 cells were used to induce prostate tumors in C57/B16 mice.
- Animals received the chemotherapeutic formulation, and outcomes were assessed via toxicology, tumor volume, and histopathology.
Main Results:
- The Heterodinuclear copper(II)Mn(II) complex-P85 combination demonstrated a steady decrease in tumor formation and volume.
- Toxicology analysis identified an optimal dosage (0.5 mg/kg Schiff base with 0.05% P85) with acceptable safety parameters.
Conclusions:
- The Heterodinuclear copper(II)Mn(II) complex-P85 formulation exhibits significant anti-cancer activity in vivo.
- This combination represents a promising novel therapeutic approach for prostate cancer.
